The Role of Liver Cancer Stem Cells in Hepatocellular Carcinoma Metastasis

Overview

Journal Cancer Biol Ther

Specialties Oncology
Pharmacology

Date 2024 Feb 23

PMID 38393655

Authors

Qinghui Niu

Susu Ye

Liu Zhao

Yanzhi Qian

Fengchao Liu

Affiliations

Soon will be listed here.

Abstract

Metastasis accounts for the vast majority of cancer deaths; however, this complex process has yet to be fully explained. To form metastases, cancer cells must undergo a series of steps, known as the "Metastatic cascade", each of which requires a specific functional transformation. Cancer stem cells (CSCs) play a vital role in tumor metastasis, but their dynamic behavior and regulatory mechanisms have not been fully elucidated. Based on the "Metastatic cascade" theory, this review summarizes the effect of liver CSCs on the metastatic biological programs that underlie the dissemination and metastatic growth of cancer cells. Liver CSCs have the capacity to initiate distant organ metastasis via EMT, and the microenvironment transformation that supports the ability of these cells to disseminate, evade immune surveillance, dormancy, and regenerate metastasis. Understanding the heterogeneity and traits of liver CSCs in these processes is critical for developing strategies to prevent and treat metastasis of advanced hepatocellular carcinoma (HCC).

Citing Articles

METTL14 suppresses the migration and invasion of hepatocellular carcinoma cells by m6A methylation of RPLP2.

Rong H, Jiang Y Sci Rep. 2025; 15(1):5660.

PMID: 39955344 PMC: 11830075. DOI: 10.1038/s41598-025-87701-5.

Betaine inhibits the stem cell-like properties of hepatocellular carcinoma by activating autophagy via SAM/mA/YTHDF1-mediated enhancement on ATG3 stability.

Wang C, Li M, Huang W, Huang S, Wusiman M, Liu Z Theranostics. 2025; 15(5):1949-1965.

PMID: 39897540 PMC: 11780527. DOI: 10.7150/thno.102682.

VIM-AS1, which is regulated by CpG methylation, cooperates with IGF2BP1 to inhibit tumor aggressiveness via EPHA3 degradation in hepatocellular carcinoma.

Han S, Ko J, Jung S, Oh S, Kim D, Kang E Exp Mol Med. 2024; 56(12):2617-2630.

PMID: 39617786 PMC: 11671536. DOI: 10.1038/s12276-024-01352-6.

Overview of hepatocarcinogenesis focusing on cellular origins of liver cancer stem cells: a narrative review.

Eun J J Yeungnam Med Sci. 2024; 42:3.

PMID: 39523770 PMC: 11812091. DOI: 10.12701/jyms.2024.01088.

Targeting the Hippo/YAP1 signaling pathway in hepatocellular carcinoma: From mechanisms to therapeutic drugs (Review).

Li S, Hao L, Li N, Hu X, Yan H, Dai E Int J Oncol. 2024; 65(3).

PMID: 39092548 PMC: 11302957. DOI: 10.3892/ijo.2024.5676.

References

Yang Z, Ngai P, Ho D, Yu W, Ng M, Lau C . Identification of local and circulating cancer stem cells in human liver cancer. Hepatology. 2008; 47(3):919-28. DOI: 10.1002/hep.22082. View

Yin X, Zhang B, Zheng S, Gao D, Qiu S, Wu W . Coexpression of gene Oct4 and Nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/Snail signaling. J Hematol Oncol. 2015; 8:23. PMC: 4377043. DOI: 10.1186/s13045-015-0119-3. View

Huan H, Yang D, Wen X, Chen X, Zhang L, Wu L . HOXB7 accelerates the malignant progression of hepatocellular carcinoma by promoting stemness and epithelial-mesenchymal transition. J Exp Clin Cancer Res. 2017; 36(1):86. PMC: 5483250. DOI: 10.1186/s13046-017-0559-4. View

Wei Z, Jia J, Heng G, Xu H, Shan J, Wang G . Sirtuin-1/Mitochondrial Ribosomal Protein S5 Axis Enhances the Metabolic Flexibility of Liver Cancer Stem Cells. Hepatology. 2019; 70(4):1197-1213. DOI: 10.1002/hep.30622. View

Wei R, Zhu W, Yu G, Wang X, Gao C, Zhou X . S100 calcium-binding protein A9 from tumor-associated macrophage enhances cancer stem cell-like properties of hepatocellular carcinoma. Int J Cancer. 2020; 148(5):1233-1244. DOI: 10.1002/ijc.33371. View

Zhang H, Chen P, Yan H, Fu G, Luo F, Zhang J . Targeting mTORC2/HDAC3 Inhibits Stemness of Liver Cancer Cells Against Glutamine Starvation. Adv Sci (Weinh). 2022; 9(20):e2103887. PMC: 9284171. DOI: 10.1002/advs.202103887. View

Li B, Cao Y, Meng G, Qian L, Xu T, Yan C . Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway. EBioMedicine. 2018; 39:239-254. PMC: 6355660. DOI: 10.1016/j.ebiom.2018.11.063. View

Chen Y, Wang W, Che L, Lan Y, Zhang L, Zhan D . BNIP3L-Dependent Mitophagy Promotes HBx-Induced Cancer Stemness of Hepatocellular Carcinoma Cells via Glycolysis Metabolism Reprogramming. Cancers (Basel). 2020; 12(3). PMC: 7139741. DOI: 10.3390/cancers12030655. View

Nio K, Yamashita T, Kaneko S . The evolving concept of liver cancer stem cells. Mol Cancer. 2017; 16(1):4. PMC: 5282887. DOI: 10.1186/s12943-016-0572-9. View

10.

Govaert K, Emmink B, Nijkamp M, Cheung Z, Steller E, Fatrai S . Hypoxia after liver surgery imposes an aggressive cancer stem cell phenotype on residual tumor cells. Ann Surg. 2013; 259(4):750-9. DOI: 10.1097/SLA.0b013e318295c160. View

11.

Kai F, Drain A, Weaver V . The Extracellular Matrix Modulates the Metastatic Journey. Dev Cell. 2019; 49(3):332-346. PMC: 6527347. DOI: 10.1016/j.devcel.2019.03.026. View

12.

Govaere O, Wouters J, Petz M, Vandewynckel Y, Van den Eynde K, Van Den Broeck A . Laminin-332 sustains chemoresistance and quiescence as part of the human hepatic cancer stem cell niche. J Hepatol. 2015; 64(3):609-17. DOI: 10.1016/j.jhep.2015.11.011. View

13.

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

14.

Jing L, Ruan Z, Sun H, Li Q, Han L, Huang L . Epithelial-mesenchymal transition induced cancer-stem-cell-like characteristics in hepatocellular carcinoma. J Cell Physiol. 2019; 234(10):18448-18458. DOI: 10.1002/jcp.28480. View

15.

Nio K, Yamashita T, Okada H, Kondo M, Hayashi T, Hara Y . Defeating EpCAM(+) liver cancer stem cells by targeting chromatin remodeling enzyme CHD4 in human hepatocellular carcinoma. J Hepatol. 2015; 63(5):1164-72. DOI: 10.1016/j.jhep.2015.06.009. View

16.

Sun L, Zhang L, Chen J, Li C, Sun H, Wang J . Activation of Tyrosine Metabolism in CD13+ Cancer Stem Cells Drives Relapse in Hepatocellular Carcinoma. Cancer Res Treat. 2020; 52(2):604-621. PMC: 7176959. DOI: 10.4143/crt.2019.444. View

17.

Schrader J, Gordon-Walker T, Aucott R, van Deemter M, Quaas A, Walsh S . Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells. Hepatology. 2011; 53(4):1192-205. PMC: 3076070. DOI: 10.1002/hep.24108. View

18.

Liu C, Liu L, Chen X, Cheng J, Zhang H, Zhang C . LSD1 Stimulates Cancer-Associated Fibroblasts to Drive Notch3-Dependent Self-Renewal of Liver Cancer Stem-like Cells. Cancer Res. 2017; 78(4):938-949. DOI: 10.1158/0008-5472.CAN-17-1236. View

19.

Mitra A, Yan J, Xia X, Zhou S, Chen J, Mishra L . IL6-mediated inflammatory loop reprograms normal to epithelial-mesenchymal transition metastatic cancer stem cells in preneoplastic liver of transforming growth factor beta-deficient β2-spectrin mice. Hepatology. 2016; 65(4):1222-1236. PMC: 5360560. DOI: 10.1002/hep.28951. View

20.

Wang C, Jiang X, Huang B, Zhou W, Cui X, Zheng C . Inhibition of matrix stiffness relating integrin β1 signaling pathway inhibits tumor growth in vitro and in hepatocellular cancer xenografts. BMC Cancer. 2021; 21(1):1276. PMC: 8620230. DOI: 10.1186/s12885-021-08982-3. View